TrialNature communications2022

A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.

Biyun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.